Troy Henderson
Primary Care · Fultondale, ALNPI 1609324003
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.5% of the total across 1,030 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 57 manufacturers, the largest accounting for just 11.0% — the pattern of someone who eats at a lot of different presentations. Among primary care clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,030 payments — averaging $17.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- GSK$2K
- Novo Nordisk$2K
- Medtronic$1K
- Boehringer Ingelheim$1K
- Bayer$1K
- plus $9K from 51 others
What the payments were for
- Travel & lodging$9785%
- Food & beverage$17,04395%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$861
- JARDIANCE$122
How this compares
$18,033 in reported general payments places this provider in the 95th percentile of 159 primary care providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 73 | $72,854 |
| MounjaroTirzepatide | 55 | $63,153 |
| OzempicSemaglutide | 54 | $58,480 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 55 | $53,677 |
| JardianceEmpagliflozin | 49 | $36,405 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $27,732 |
| FarxigaDapagliflozin Propanediol | 23 | $24,689 |
| Repatha SureclickEvolocumab | 25 | $23,190 |
| XareltoRivaroxaban | 24 | $22,399 |
| Tresiba Flextouch U-200Insulin Degludec | 25 | $19,503 |
| KerendiaFinerenone | 12 | $15,104 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $14,554 |
| Xigduo XrDapaglifloz Propaned/Metformin | 21 | $14,161 |
| MyrbetriqMirabegron | 20 | $14,061 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 16 | $9,713 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $856 | $72,85473 claims |
| Lilly USA, LLCMounjaro | $1,025 | $63,15355 claims |
| Novo NordiskOzempic | $1,845 | $58,48054 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $1,197 | $45,62763 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $1,943 | $36,83743 claims |
| AstraZenecaFarxiga | $1,019 | $24,68923 claims |
| Johnson & JohnsonXarelto | $165 | $22,39924 claims |
| BayerKerendia | $1,189 | $15,10412 claims |
| Astellas Pharma US IncMyrbetriq | $139 | $14,06120 claims |
| AbbVieSynthroid | $1,980 | $1,58217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 159 primary care providers in Alabama.
Other primary care in Fultondale
- Keith MatthewsOpelika$20K
- April TateDothan$16K
- Brandy McGrawMobile$14K
- Cleo ValdezHuntsville$14K
- Larissa RobinsonJasper$11K
- Jamie GhrigsbyMoulton$9K
- Josh WarrenBirmingham$9K
- Amber NelsonHoover$9K
- Valerie ZiemanFoley$8K
- Tammy CorneliusCullman$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.